Zacks Research Decreases Earnings Estimates for Cytosorbents

Cytosorbents Corporation (NASDAQ:CTSO) – Zacks Research decreased their Q3 2026 earnings per share (EPS) estimates for shares of Cytosorbents in a research note issued to investors on Monday, August 17th. Zacks Research analyst T. Kerr now forecasts that the medical research company will post earnings per share of ($0.05) for the quarter, down from their previous forecast of ($0.04). The consensus estimate for Cytosorbents’ current full-year earnings is ($0.21) per share. Zacks Research also issued estimates for Cytosorbents’ FY2026 earnings at ($0.22) EPS and FY2027 earnings at ($0.09) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cytosorbents in a research note on Monday, July 6th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Cytosorbents presently has a consensus rating of “Hold” and an average price target of $5.38.

Cytosorbents Trading Down 1.1%

Shares of NASDAQ CTSO opened at $0.36 on Thursday. The company has a quick ratio of 0.50, a current ratio of 0.66 and a debt-to-equity ratio of 4.70. Cytosorbents has a 12 month low of $0.35 and a 12 month high of $1.04. The company has a market cap of $22.37 million, a price-to-earnings ratio of -1.23 and a beta of 1.39. The business has a fifty day simple moving average of $0.39 and a 200-day simple moving average of $0.53.

Cytosorbents (NASDAQ:CTSO) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.03). The company had revenue of $9.63 million during the quarter, compared to analyst estimates of $9.38 million. Cytosorbents had a negative return on equity of 431.65% and a negative net margin of 48.94%.

Insider Buying and Selling

In other news, CEO Phillip P. Chan acquired 251,136 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The stock was purchased at an average price of $0.40 per share, with a total value of $100,454.40. Following the purchase, the chief executive officer owned 1,734,099 shares of the company’s stock, valued at approximately $693,639.60. This trade represents a 16.93% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 7.80% of the company’s stock.

Institutional Trading of Cytosorbents

A number of hedge funds have recently modified their holdings of CTSO. Citadel Advisors LLC boosted its position in shares of Cytosorbents by 127.3% in the third quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock worth $61,000 after buying an additional 36,790 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Cytosorbents by 149.2% during the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after buying an additional 37,519 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new position in Cytosorbents during the third quarter valued at $161,000. CM Management LLC raised its position in Cytosorbents by 14.6% during the fourth quarter. CM Management LLC now owns 1,476,500 shares of the medical research company’s stock valued at $944,000 after buying an additional 188,372 shares during the period. Finally, Vanguard Group Inc. raised its position in Cytosorbents by 3.7% during the third quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after buying an additional 79,535 shares during the period. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.